Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05239884 · ClinicalTrials.gov registry record · NA
CSD201202: A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery System P12
A NA study of Smoking and Tobacco Use, sponsored by RAI Services Company.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05239884: Completed NA study of Smoking and Tobacco Use, sponsored by RAI Services Company.
NCT05239884 is a NA study of Smoking and Tobacco Use that has completed, run by RAI Services Company. The registered enrollment target is 36 participants, below the 455-participant average among 123 other Smoking trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05239884, a NA study of Smoking and Tobacco Use, has completed, sponsored by RAI Services Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, randomized, 8-way crossover study designed to evaluate plasma nicotine pharmacokinetic (PK) parameters following an ad libitum use of Electronic Nicotine Delivery System (ENDS) investigational products (IPs) in a confinement setting by generally healthy combustible cigarette (CC) smokers and dual users of CC and ENDS.
Primary Outcome
Baseline-adjusted area under the plasma nicotine concentration-versus-time curve from time zero to 240 minutes after the start of IP use. A relative estimate of nicotine absorption that results from a single use of each of the ENDS IP.
Conditions Studied
Interventions
- OTHER ENDS Product A with 1.5% nicotine
- OTHER ENDS Product B with 1.5% nicotine
- OTHER ENDS Product C with 1.5% nicotine
- OTHER ENDS Product D with 1.5% nicotine
- OTHER ENDS Product E with 1.5% nicotine
Study Locations (1)
North Carolina
- High Point Clinical Trials Center - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2022-04-15 |
| Phase | NA |
What the finished NCT05239884 record still lists
NCT05239884 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 455-participant average among 123 other Smoking trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Smoking appearing as the primary indexed condition, and to 5 interventions - of which ENDS Product A with 1.5% nicotine is the first listed.
NCT05239884 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05239884 about?
NCT05239884 is a clinical study titled "CSD201202: A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery System P12". This is an open-label, randomized, 8-way crossover study designed to evaluate plasma nicotine pharmacokinetic (PK) parameters following an ad libitum use of Electronic Nicotine Delivery System (ENDS) investigational products (IPs) in a confinement setting by generally healthy combustible cigarette (...
What is the current status of trial NCT05239884?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2022-03-14. Estimated completion is 2022-04-15.
What conditions does trial NCT05239884 study?
This clinical trial studies the following conditions: Smoking, Tobacco Use.
What interventions are being tested in trial NCT05239884?
The interventions under investigation include: ENDS Product A with 1.5% nicotine (OTHER), ENDS Product B with 1.5% nicotine (OTHER), ENDS Product C with 1.5% nicotine (OTHER), ENDS Product D with 1.5% nicotine (OTHER), ENDS Product E with 1.5% nicotine (OTHER).
Who is sponsoring clinical trial NCT05239884?
This trial is sponsored by RAI Services Company, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05239884 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05239884's enrollment target sits among peer trials
36 108th of 123 higher than 16 of 123 other Smoking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Alternatives for Reducing Harm Using E-cigarettes
RECRUITING · NA
-
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
RECRUITING · NA
-
Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network
RECRUITING · NA
-
Enhancing Motivation to Quit Smoking Via Self-Help Intervention Targeted to Cancer Type
RECRUITING · NA
-
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
RECRUITING · NA
-
Take A Break - Rural
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI